Remsima acquires IBD indication in Canada, accelerating expansion into NA market

Celltrion announced it acquired an addition indication of inflammatory bowel disease(IBD) for its autoimmune disease therapy, antibody biosimilar ‘Remsima(local name: Inflectra)’ from the Health Canada on June 10(local time).

The company acquired sales approval of ‘Remsima’ on indications such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis from the Canadian ...